🔍

BLISSGVS - Bliss GVS Pharma

📊 NSE: BLISSGVS 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/13/2025 19:34

📢 Recent Corporate Announcements

Bliss GVS Pharma Announces TDS Guidelines for Re. 0.50 Interim Dividend; Record Date Feb 18

🟡 NEUTRAL ⭐ 6/10

DIVIDEND 📅 17 Feb 2026, 07:48 PM

Bliss GVS Pharma has declared an interim dividend of Re. 0.50 per equity share for the financial year 2025-2026. The company has established February 18, 2026, as the record date to identify eligible shareholders for this payout. This communication outlines the Tax Deduction at Source (TDS) procedures, where a 10% tax will be deducted for resident shareholders with a valid PAN. Shareholders must submit necessary tax exemption forms like 15G/15H by February 23, 2026, to avoid higher tax withholding.

Interim dividend of Re. 0.50 per equity share (50% of face value) declared for FY 2025-26.
Record date for dividend eligibility is fixed as Wednesday, February 18, 2026.
TDS of 10% applies to resident shareholders with PAN; 20% applies if PAN is invalid or not linked to Aadhaar.
No TDS for resident individuals if the total dividend received during FY 2025-26 does not exceed Rs. 10,000.
Deadline for submitting tax-related documents (Form 15G/15H/TRC) is Monday, February 23, 2026.

💡 Shareholders should ensure their PAN and Aadhaar are linked and bank details are updated in their demat accounts to receive the dividend smoothly. If eligible for tax exemption, submit Form 15G/15H to the company's registrar by the February 23 deadline.

Bliss GVS Pharma Clarifies Speculative News Regarding Stake Sale to Anupam Rasayan

🔵 WATCH ⭐ 7/10

M&A 📅 13 Feb 2026, 11:22 AM

Bliss GVS Pharma has officially addressed a news report from CNBC Awaaz dated February 13, 2026, which suggested that Anupam Rasayan might acquire a stake in the company. The company clarified that this news is speculative and did not originate from any official communication. As of the current date, no arrangement or decision regarding a stake sale has been finalized or approved by the promoters. The disclosure was made under Regulation 30(11) to prevent the establishment of false market sentiment.

Company denies CNBC Awaaz report titled 'Bliss GVS में हिस्सा ले सकती है अनुपम रसायन' as speculative.
Management confirms no decision or arrangement has been crystallized or approved by promoters as of Feb 13, 2026.
Clarification issued under SEBI Regulation 30(11) to maintain market integrity.
Investors advised to rely only on official exchange filings rather than media reports.

💡 Investors should remain cautious and avoid reacting to unverified media reports, as the company has officially denied any finalized deal. Monitor the stock for volatility but prioritize official regulatory filings for investment decisions.

Bliss GVS Pharma Appoints Pralay Roy as GM - Procurement; Brings 23+ Years Experience

🟢 POSITIVE ⭐ 4/10

MANAGEMENT 📅 12 Feb 2026, 07:15 PM

Bliss GVS Pharma Limited has appointed Mr. Pralay Roy as General Manager – Procurement and a member of the Senior Management Personnel, effective February 12, 2026. Mr. Roy brings over 23 years of specialized experience in pharmaceutical procurement, focusing on global sourcing of APIs, excipients, and packaging materials. His previous leadership roles at companies like Bristol Laboratories and Unichem Laboratories suggest a strong background in cost optimization and supply chain planning. This appointment is aimed at strengthening the company's operational efficiency and vendor management strategies.

Appointment of Mr. Pralay Roy as General Manager – Procurement effective February 12, 2026
Mr. Roy possesses over 23 years of experience in pharmaceutical supply chain and global sourcing
Expertise includes managing procurement for APIs, excipients, and packaging materials across major pharma firms
Previous experience includes senior roles at Bristol Laboratories, Unichem Laboratories, and RPG Life Sciences

💡 This is a routine senior management appointment that strengthens the company's procurement capabilities. Investors should view this as a positive step toward operational efficiency but no immediate stock action is required.

Bliss GVS Pharma: Two Whole-Time Directors Resign Effective February 10, 2026

🔵 WATCH ⭐ 6/10

MANAGEMENT 📅 10 Feb 2026, 06:25 PM

Bliss GVS Pharma Limited has announced the resignation of two Whole-Time Directors, Mrs. Shruti Vishal Rao and Dr. Vibha Gagan Sharma, effective February 10, 2026. Both directors are daughters of the current Managing Director and CEO, Mr. Narsimha Shibroor Kamath, and cited other professional commitments as the reason for their departure. The Board accepted these resignations in a meeting held at shorter notice on the same day. This simultaneous exit of two family-member directors from the board marks a significant change in the company's executive leadership structure.

Resignation of Mrs. Shruti Vishal Rao and Dr. Vibha Gagan Sharma as Whole-Time Directors effective Feb 10, 2026.
Both outgoing directors are daughters of the Managing Director & CEO, Mr. Narsimha Shibroor Kamath.
The resignations were attributed to other professional commitments by the directors.
The Board meeting to accept the resignations was held at shorter notice on February 10, 2026, between 5:30 PM and 6:00 PM.
Both individuals will also cease to be members of all company committees effective immediately.

💡 Investors should monitor for any new board appointments to understand if the company is moving towards more professional management or if other family members will be inducted. The simultaneous exit of two promoter-related directors warrants a watch on the company's future succession and governance strategy.

Bliss GVS Pharma Declares 50% Interim Dividend; Sets Feb 18 as Record Date

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 10 Feb 2026, 05:10 PM

Bliss GVS Pharma Limited has announced an interim dividend of ₹0.50 per equity share for the financial year 2025-2026. This payout represents 50% of the face value of ₹1 per share. The company has officially fixed Wednesday, February 18, 2026, as the record date to determine shareholder eligibility. The dividend is expected to be disbursed to eligible shareholders within 30 days of its declaration on February 10, 2026.

Interim dividend of ₹0.50 per equity share (50% of face value ₹1) declared
Record date for dividend eligibility fixed as February 18, 2026
Dividend declared for the Financial Year 2025-2026
Payment to be completed within 30 days from the declaration date of February 10, 2026

💡 Investors interested in the dividend should ensure they hold the shares before the ex-dividend date to be eligible for the ₹0.50 per share payout. This announcement reflects a positive cash return to shareholders for the current fiscal year.

Bliss GVS Pharma Updates KMP Contact Details for Material Event Disclosures

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Feb 2026, 05:08 PM

Bliss GVS Pharma has updated its list of Key Managerial Personnel (KMP) authorized to determine and disclose material events under SEBI regulations. Mr. Narsimha Shibroor Kamath (MD & CEO) and Mr. Deepak Sawant (CFO) are now the designated authorities for determining the materiality of information. Ms. Aditi Bhatt, the Company Secretary, remains the authorized person for making the actual disclosures to the stock exchanges. This update is a standard compliance requirement under Regulation 30(5) of SEBI (LODR) 2015.

Designated MD & CEO Narsimha Shibroor Kamath and CFO Deepak Sawant to determine event materiality
Authorized Company Secretary Aditi Bhatt to communicate material disclosures to BSE and NSE
Compliance update filed under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) 2015
Centralized contact details provided including office number 022-42160000 and email cs@blissgvs.com

💡 This is a routine administrative update regarding regulatory compliance. No action is required as it does not impact the company's financial health or business operations.

Bliss GVS Pharma Updates KMP Contact Details for Material Event Reporting

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Feb 2026, 05:05 PM

Bliss GVS Pharma Limited has updated its list of Key Managerial Personnel (KMP) authorized to determine and disclose material events to stock exchanges. Mr. Narsimha Shibroor Kamath (MD & CEO) and Mr. Deepak Sawant (CFO) are now the designated authorities for determining the materiality of information. Ms. Aditi Bhatt, the Company Secretary, has been authorized to handle the actual disclosure process to the BSE and NSE. This filing is a mandatory compliance requirement under Regulation 30(5) of SEBI (LODR) Regulations, 2015.

Mr. Narsimha Shibroor Kamath (MD & CEO) and Mr. Deepak Sawant (CFO) authorized to determine event materiality
Ms. Aditi Bhatt (Company Secretary) designated for intimating material events to Stock Exchanges
Compliance update submitted under Regulation 30(5) of SEBI (LODR) Regulations, 2015
Official contact details provided include phone 022-42160000 and email cs@blissgvs.com

💡 This is a routine administrative update with no impact on company fundamentals. No specific action is required from investors.

Bliss GVS Pharma Declares Interim Dividend of Rs 0.50 Per Share; Sets Record Date

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 10 Feb 2026, 03:11 PM

Bliss GVS Pharma has declared an interim dividend of Rs 0.50 per equity share for the financial year 2025-26, which represents 50% of the face value of Re 1. The company has fixed February 18, 2026, as the record date to determine shareholder eligibility for this payout. This announcement was made alongside the approval of the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The dividend is scheduled to be paid to eligible shareholders within 30 days of its declaration.

Interim dividend declared at Rs 0.50 per equity share (50% of face value)
Record date for dividend eligibility fixed as February 18, 2026
Dividend payment to be completed within 30 days from February 10, 2026
Approved unaudited standalone and consolidated financial results for Q3 FY26

💡 Investors interested in the dividend should ensure they hold the shares before the record date of February 18, 2026. Additionally, shareholders should review the Q3 financial results to assess the company's operational performance.

Bliss GVS Pharma Approves Q3 FY26 Results; Declares 50% Interim Dividend

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 10 Feb 2026, 03:08 PM

Bliss GVS Pharma Limited has approved its standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. In a positive move for shareholders, the Board declared an interim dividend of 50%, amounting to ₹0.50 per equity share on a face value of ₹1. The company has fixed February 18, 2026, as the record date for dividend eligibility. The dividend is scheduled to be paid within 30 days of the declaration.

Approved unaudited standalone and consolidated financial results for Q3 and 9M FY2025-26.
Declared an interim dividend of 50%, which is ₹0.50 per equity share of face value ₹1.
Fixed Wednesday, February 18, 2026, as the record date for determining eligible shareholders.
Committed to paying the interim dividend within 30 days from the date of declaration.

💡 Investors interested in the dividend should ensure they hold the shares before the record date of February 18, 2026. A detailed review of the full financial results is recommended to assess the company's underlying growth and margin performance.

Bliss GVS Pharma Declares ₹0.50 Interim Dividend; Sets Feb 18 as Record Date

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 10 Feb 2026, 03:02 PM

Bliss GVS Pharma has declared an interim dividend of ₹0.50 per equity share for the financial year 2025-2026, representing a 50% payout on the face value of ₹1. The Board has fixed February 18, 2026, as the record date to determine eligible shareholders for this payment. This announcement was made alongside the approval of the company's unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The dividend is mandated to be paid within 30 days of its declaration.

Interim dividend of ₹0.50 per equity share declared (50% of face value).
Record date for dividend eligibility set for February 18, 2026.
Dividend payment to be completed within 30 days from February 10, 2026.
Board approved unaudited financial results for Q3 and 9M ended December 31, 2025.

💡 Investors looking to benefit from the dividend should ensure they hold the stock before the record date of February 18, 2026. Additionally, shareholders should review the Q3 financial results to evaluate the company's underlying earnings strength.

Bliss GVS Shareholders Approve Narsimha Kamath as Managing Director with 99.9% Majority

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 30 Jan 2026, 06:12 PM

Bliss GVS Pharma Limited has announced the successful passage of a special resolution to appoint Mr. Narsimha Shibroor Kamath as Managing Director. The resolution was passed via postal ballot with an overwhelming majority of 99.90% of the votes cast in favour. A total of 6.37 crore votes were polled, representing approximately 60.21% of the total shareholding. The promoter group and public institutions showed unanimous support for the appointment, indicating strong internal and institutional alignment.

Special resolution passed for the appointment of Mr. Narsimha Shibroor Kamath as Managing Director
Total votes polled reached 6,36,93,053, representing 60.21% of the total 10.58 crore shares
The appointment received 99.90% approval (6,36,26,720 votes) from participating shareholders
Promoter group and Public Institutions voted 100% in favour of the resolution
Only 0.10% of votes (66,333) were cast against the proposal

💡 Investors should view this as a positive sign of leadership continuity and strong shareholder backing. No immediate action is required, but monitoring the new MD's strategic direction for the company is advised.

Bliss GVS Pharma Incorporates New Step-Down Subsidiary in Democratic Republic of the Congo

🟢 POSITIVE ⭐ 4/10

EXPANSION 📅 27 Jan 2026, 06:37 PM

Bliss GVS Pharma Limited, through its Singapore-based wholly owned subsidiary Bliss GVS International PTE Ltd, has incorporated a new step-down subsidiary in the Democratic Republic of the Congo. The new entity, Theralife Pharma RDC Private Limited, is located in Kinshasa and will operate in the pharmaceutical and health sector. The subsidiary was incorporated on December 26, 2025, with an initial share capital of USD 1,000. This move indicates the company's continued focus on expanding its footprint in the African market.

Incorporation of Theralife Pharma RDC Private Limited as a 100% step-down subsidiary.
Initial share capital of USD 1,000 comprising 100 equity shares of USD 10 each.
Strategic expansion into the pharmaceutical and health sector in Kinshasa, Democratic Republic of the Congo.
Ownership held through Bliss GVS International PTE Ltd, Singapore.
Entity incorporated on December 26, 2025, with no prior turnover history.

💡 Investors should view this as a routine geographical expansion into the African market. While the initial investment is nominal, monitor future updates regarding operational scale-up and revenue contribution from this new region.

Bliss GVS Pharma Submits SEBI Compliance Certificate for Q3 FY2025-26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 05 Jan 2026, 11:56 AM

Bliss GVS Pharma has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Registrar MUFG Intime India Private Limited, confirms that all share dematerialization requests for the quarter ended December 31, 2025, were processed within the mandated timelines. It also verifies that the physical certificates were mutilated and cancelled, and the names of the depositories were updated in the register of members. This filing is a standard administrative requirement and confirms the company's adherence to depository regulations.

Compliance certificate submitted for the quarter ended December 31, 2025.
Registrar MUFG Intime India confirmed processing of all dematerialization requests.
Securities comprised in the certificates are listed on the NSE and BSE.
Physical share certificates were mutilated and cancelled after due verification.
The filing confirms adherence to SEBI (Depositories and Participants) Regulations, 2018.

💡 No action is required from investors as this is a routine regulatory filing. Investors should continue to monitor the company's upcoming quarterly financial performance for material impact.

Bliss GVS Pharma Proposes Appointment of Narsimha Shibroor Kamath as Managing Director

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 30 Dec 2025, 04:49 PM

Bliss GVS Pharma has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Narsimha Shibroor Kamath as Managing Director for a three-year term. Mr. Kamath, who currently serves as the Chief Executive Officer, will be redesignated as Managing Director & CEO upon approval. As he is 72 years old, the company is seeking a special resolution to confirm that his continued leadership is in the best interest of the firm. The e-voting process for shareholders will run from December 31, 2025, to January 29, 2026.

Proposed appointment of current CEO Mr. Narsimha Shibroor Kamath as Managing Director for a 3-year tenure.
Special resolution required due to the appointee's age of 72 years as per Companies Act requirements.
E-voting period scheduled from December 31, 2025, to January 29, 2026, with results by February 2, 2026.
The appointee will hold the dual designation of Managing Director & Chief Executive Officer.
The board has appointed Mr. Vijay Yadav of AVS & Associates as the scrutinizer for the voting process.

💡 Investors should monitor the voting results to ensure leadership continuity and review the detailed explanatory statement for specifics on the proposed remuneration package.

Bliss GVS Pharma Announces Trading Window Closure from January 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Dec 2025, 12:45 PM

Bliss GVS Pharma Limited has announced the closure of its trading window effective from January 01, 2026. This action is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's financial results. The closure applies to all designated persons and their immediate relatives until 48 hours after the announcement of the unaudited financial results for the quarter and nine months ended December 31, 2025. The specific date for the board meeting to approve these results will be communicated at a later time.

Trading window closure begins on Thursday, January 01, 2026.
Closure is in preparation for the financial results for the quarter and nine months ended December 31, 2025.
The restriction will be lifted 48 hours after the financial results are made public.
The date for the Board Meeting to consider results is yet to be announced.

💡 This is a routine regulatory announcement with no immediate impact on stock fundamentals. Investors should wait for the announcement of the board meeting date to assess the upcoming quarterly performance.

View All BLISSGVS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue from operations grew by 5.91% YoY to INR 846.22 Cr in FY25, driven by a portfolio of 250+ branded formulations across 20+ therapeutic segments. Standalone revenue increased by 10.09% to INR 703.42 Cr, primarily supported by higher volumes in international markets like Nigeria and Kenya.

Geographic Revenue Split

The company is highly export-oriented with 93% of total revenue generated from international markets. The primary focus is the Sub-Saharan African region, including Nigeria, Kenya, and Ghana, which accounts for the vast majority of sales.

Profitability Margins

Consolidated Net Profit (PAT) margin improved to 11.14% in FY25 from 10.59% in FY24. Standalone PAT margins saw a significant recovery, with standalone net profit rising 36.19% to INR 68.97 Cr in FY25 from INR 50.64 Cr in FY24, reflecting better operational efficiencies and cost management.

EBITDA Margin

Standalone EBITDA margin improved to 17.70% in FY24 from 15.07% in FY23, a growth of 263 bps. This was driven by a shift toward higher-margin branded formulations and leadership in the specialized suppositories and pessaries segment.

Capital Expenditure

The company successfully commissioned an additional 2.5 MW solar capacity in Q4 FY25 to reduce energy costs. While specific total INR Cr for future capex is not disclosed, the company maintains a healthy capital structure with a low gearing of 0.07x, providing significant headroom for debt-funded expansion.

Credit Rating & Borrowing

CRISIL assigned 'CRISIL BBB+/Stable/A2' ratings in June 2024. The company's borrowing costs are supported by a healthy financial risk profile, with interest coverage at 17.67x in FY25 and a low reliance on external funds (Total Debt of INR 77.50 Cr against a Net Worth of INR 983.14 Cr).

⚙️ Operational Drivers

Raw Materials

Key raw materials include Active Pharmaceutical Ingredients (APIs) and specialized excipients for suppositories and pessaries. While specific % of total cost per material is not disclosed, volatility in raw material prices is cited as a primary risk to profitability margins.

Import Sources

Manufacturing is concentrated in Maharashtra, India (5 units) and Nigeria (2 units). Raw materials are sourced to support these locations, with a significant portion of finished goods exported back to African markets.

Key Suppliers

Not specifically disclosed, but the company maintains long-term relationships with suppliers established over 35 years of operations.

Capacity Expansion

Current manufacturing infrastructure consists of 7 units (5 in India, 2 in Nigeria). Recent expansion includes the 2.5 MW solar power project to enhance energy resilience. Future expansion is targeted toward regulated markets.

Raw Material Costs

Raw material price volatility is a key sensitivity factor. The company manages this through established supplier relationships and its position as a contract manufacturer for majors like Sun Pharma and Mankind, which helps stabilize procurement scales.

Manufacturing Efficiency

The company is a world leader in suppositories and pessaries, a niche dosage form that requires specialized manufacturing capabilities, providing a competitive edge over general formulation players.

Logistics & Distribution

Distribution is a critical cost component given the 93% export focus. The company utilizes its Singapore and UK subsidiaries (Bliss GVS International and Asterisk Lifesciences) to manage global logistics and trading.

📈 Strategic Growth

Expected Growth Rate

20%

Growth Strategy

Growth will be achieved by expanding into regulated markets, launching new products in the 20+ therapeutic segments already served, and increasing penetration in the African market through new subsidiaries like Theralife Pharma Ltd in Kenya (incorporated Nov 2025).

Products & Services

Branded formulations including suppositories, pessaries, capsules, tablets, and syrups. Therapeutic focus includes anti-malarial, anti-fungal, anti-bacterial, and anti-inflammatory medicines.

Brand Portfolio

Bliss GVS owns over 250 branded formulations; it holds leadership positions in the anti-malarial and anti-fungal segments in Sub-Saharan Africa.

New Products/Services

The company continues to expand its 250+ product portfolio. It recently incorporated Theralife Pharma Ltd in Kenya to strengthen its local presence and product delivery in the East African region.

Market Expansion

Expansion is focused on moving from semi-regulated African markets into highly regulated global markets to diversify the revenue base and reduce geographic concentration.

Market Share & Ranking

Global leader in the manufacturing of suppositories and pessaries dosage forms.

Strategic Alliances

The company contract-manufactures specialized dosage forms (suppositories/pessaries) for major pharma companies including Sun Pharma, Mankind, Sanofi, and Alkem, though these partners do not have export rights for these specific products.

🌍 External Factors

Industry Trends

The industry is shifting toward ESG compliance; Bliss GVS responded by commissioning 2.5 MW of solar power. There is also a trend toward specialized delivery systems (suppositories), where the company holds a dominant global position.

Competitive Landscape

Competes with global and local generic players in Africa, but maintains an edge through its specialized product portfolio and local manufacturing presence in Nigeria.

Competitive Moat

The moat is built on specialized manufacturing expertise in suppositories and pessaries, which are more complex to produce than standard tablets. This niche focus, combined with 35+ years of brand equity in Africa, creates high entry barriers.

Macro Economic Sensitivity

Highly sensitive to the economic stability of African nations. Revenue growth in FY20 was specifically attributed to economic stability in markets like Nigeria and Kenya.

Consumer Behavior

Increasing demand for branded generics in emerging markets and a shift toward more effective delivery systems for anti-malarial and anti-fungal treatments.

Geopolitical Risks

Significant exposure to the Sub-Saharan African region (93% of sales) makes the company vulnerable to local political shifts, trade barriers, and changes in regional pharmaceutical import policies.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by WHO-GMP, EU-GMP, ISO14001, and OHSAS 18001 standards. Profitability is highly vulnerable to changes in government drug pricing and import regulations in African jurisdictions.

Environmental Compliance

The company is investing in renewable energy (2.5 MW solar) to align with global ESG expectations and reduce carbon footprint.

Taxation Policy Impact

The company is subject to Indian corporate tax and local taxes in Nigeria. Effective tax management is reflected in the consolidated PAT of INR 90.26 Cr.

Legal Contingencies

Internal auditors reported no material or serious observations regarding the inadequacy of internal financial controls during the most recent review period.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the high revenue concentration (93%) in the African region and the potential for sudden regulatory changes or forex volatility to impact the INR 100 Cr+ annual cash accruals.

Geographic Concentration Risk

93% of revenue is derived from exports, with a heavy concentration in Sub-Saharan Africa.

Third Party Dependencies

The company depends on the economic health of its primary export markets and the continued demand from contract manufacturing partners like Sun Pharma and Mankind.

Technology Obsolescence Risk

The company is mitigating technology risks by investing in digitalization and infrastructure to maintain its lead in specialized dosage forms.

Credit & Counterparty Risk

Receivables management is critical due to the working capital-intensive nature of the business; however, the current ratio of 4.91x suggests a strong liquidity cushion.